Please assess the completion status of the following clinical trial:

Trial Title: Posterior Wall And Left Atrial Appendage Empiric Electrical Isolation for Non-Paroxysmal Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed and dated informed consent form~2. Stated willingness to comply with all study procedures and availability for the duration of the study~3. Male or female, aged 18 or greater~4. In good general health as evidenced by medical history and diagnosed with symptomatic persistent AF or long-standing persistent AF.~   1. Persistent AF will be defined as a sustained episode lasting \> 7 days and less than 1 year.~  2. Long-standing persistent AF will be defined as a sustained episode lasting more than 1 year and less than 10 years.~  3. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms, or any combination of the above.~5. At least one episode of persistent AF must have been documented by ECG, Holter, loop recorder, ziopatch, telemetry, trans telephonic monitoring (TTM), or implantable device within last 10 years of enrollment in this investigation.~6. Patients undergoing first time procedure for AF.~Exclusion Criteria:~1. Patients with paroxysmal AF.~   • Paroxysmal AF will be defined as a sustained episode lasting \< 7 days (either terminated spontaneously or with pharmacological or electrical cardioversion.~2. Reversible causes of AF.~3. Patients with contraindications to systemic anticoagulation with heparin or coumadin, direct thrombin inhibitor or factor Xa inhibitors.~4. Patients with left atrial size ≥ 75 mm (2D echocardiography, parasternal long axis view)~5. Left atrial or LAA thrombus~6. Patients with severe valvular heart disease or after mitral valve replacement (bioprosthetic or mechanical).~7. Patients with a life expectancy ≤ 24 months~8. CHA2DS2Vasc score of 0 for men and CHA2DS2Vasc score of 1 for women.~9. Patients who are pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- PVI (Type: ACTIVE_COMPARATOR): Pulmonary vein isolation alone will be performed using radiofrequency energy
- PVI + PWI (Type: EXPERIMENTAL): Pulmonary vein isolation plus posterior wall isolation will be performed using radiofrequency energy
- PVI + PWI + LAAEI (Type: EXPERIMENTAL): Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation will be performed using radiofrequency energy
- PVI + PWI + LAAEI + CSI (Type: EXPERIMENTAL): Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation plus coronary sinus isolation will be performed using radiofrequency energy

Based on this trial design, predict the completion outcome and termination type (if applicable).